contakt world

Contakt World to Offer Vaccine Passport and Verification Platform To Employers, Events and Organizations, Including Customers of Recently Acquired HealthCheck App

HealthCheck app provides an ideal technology environment for combined symptom screening, vaccine passport and verification

  • Contakt World intends to offer existing and new customers integrated tools for vaccine passport and verification.
  • Vaccine passport verification is critical to combat increased fraud  and reduce liability – Contakt World to deliver passport verification solution to ensure accuracy and prevent use of fraudulent vaccine records.
  • Contakt World recently acquired cash flow positive HealthCheck - a health screening tool to assess COVID-19 symptoms quickly and easily via the HealthCheck app - featuring 1,000+ locations in use.
  • News that the Pfizer BioNTech vaccine loses efficacy faster against Delta variant1 suggests a recurring need for boosters, vaccine passports, and health screening for years to come.

Contakt World Technologies Corp. (CSE: HELP) (OTC: TLOOF) (FSE: B2I0) (the "Company" or "Contakt World"), a SaaS company committed to improving health equity and access to healthcare while solving sector specific business challenges, today announced it will leverage the recently acquired HealthCheck app to help combat fraud in vaccine credentials and enable privacy-preserving vaccine passports.

COVID-19 vaccination records, when digitized, are frequently termed a "COVID-19 Vaccine Passport", "Health Pass", or "Vaccine Pass". Vaccine passports allow an organization to confirm an individual's vaccination status without the administrative burdens associated with paper cards. They also help reduce the potential fraud associated with certain paper vaccine credentials. When paired with HealthCheck's health screening in the same app, vaccine passports allow an organization to conduct daily health check-ins and validate vaccine credentials without violating personal privacy.

While some states and jurisdictions have implemented Vaccine passport technology, backed by state and government vaccination records, many have not. There still is no universal solution that works across jurisdictions. Vaccine Passport verification and validation is essential for effective rollout of vaccine mandates by private business. Contakt World's vaccine validation solution intends to leverage a number of disparate data sources to ensure validity of vaccination records beyond paper records.

HealthCheck is already used by a variety of customers, including schools, hospitals, fire stations, financial institutions, and small businesses. Justin Beck, Chief Visionary Officer for Contakt World, stated "in addition to HealthCheck's daily health check-ins, organizations will soon be able to use HealthCheck as a Vaccine Passport solution for students, teachers, customers, visitors and employees without violating personal privacy. We're working with several solution providers to enable this - we expect this will result in increased sales from existing customers, and expanded sales to new customers."

Mr. Beck added, "a close friend of mine in Oceanside, California recently shared with me the story of a small restaurant with not more than 20 employees and the drama surrounding vaccination and the need for vaccine passports experienced by her manager. One employee purported to have received two Johnson & Johnson vaccine doses in a 30-day period using what appeared to be a fraudulent 'card,' where the Johnson & Johnson vaccine is generally a single dose vaccine. Another refused to get vaccinated and refused to wear a mask. We cannot underestimate the ongoing effects on employee and customer wellness, nor the implications upon economies that vaccine passports will play, for years and years to come."

"A British study from University of Oxford/ONS recently reported via The Independent suggesting a gradual decrease in efficacy for the Pfizer against the delta variant of COVID-19 in the months immediately after receiving the vaccine. This confirms that vaccinated populations will need boosters, so effective health screening provided by Contakt World's solutions and vaccine passports (with updates to ensure they are current) are vital to global economies. Data from the study doesn't even factor the implications of other variants," Mr. Beck continued.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/8151/94332_VaccinePassports_ContaktWorld.jpg

Pfizer Vaccine Losing Efficacy Faster Against Delta Variant

To view an enhanced version of this image, please visit:
https://orders.newsfilecorp.com/files/8151/94332_VaccinePassportsContaktWorld.jpg

Other Recent News from Contakt World:

Contakt World Announces Acquisition of HealthCheck, a SaaS Health Screening App for Students, Customers, Employees, and Visitors

Contakt World Becomes Data Partner for Health Equity Tracker Project to Improve Collection of De-Identified Racial & Ethnic Minority Data Using Smart Health RM, Engagency, and Future Services

1 The chart above is from Statista, originating from The Independent's reporting:

https://www.statista.com/chart/25575/pfizer-astrazeneca-efficacy-loss/

https://www.independent.co.uk/news/science/covid-vaccine-delta-pfizer-astrazeneca-b1904782.html?r=19108

To Learn More:

To receive investor updates from Contakt World Technologies Corp. (CSE: HELP), click here.

If you are an organization seeking daily health screening and future vaccine passports, schedule a demo of HealthCheck by clicking here.

About Contakt World

Contakt World (CSE: HELP) is a technology company developing and delivering SaaS solutions for the public and private sectors. The company integrates data collection and management, communications, advertising, and IOT devices - providing customers with a scalable ecosystem that makes sense of people, place, time, and space for the emerging "phygital" (blending physical and digital) world. Contakt World is committed to improving health equity and healthcare access while solving sector-specific business challenges. For more information, please visit https://contakt.world/.

Contakt World Contact
Zayn Kalyn
Interim CEO and Director
Direct: 778-938-3367

The CSE has not reviewed, approved or disapproved the content of this news release.

Forward Looking Statements Disclaimer

This press release contains "forward-looking information" within the meaning of applicable securities laws ("forward-looking statements"), including, but not limited to, statements with respect to the future prospects of Contakt World. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the use of words such as "plans", "expects" or "does not expect", "is expected", "budget", "scheduled", "estimates", "forecasts", "projects", "intends", "anticipates" or "does not anticipate", or "believes", or variations of such words and phrases or state that certain actions, events or results "may", "could", "would", "might" or "will be taken", "occur" or "be achieved". Such forward-looking statements necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward-looking statements, including statements respecting: Healthcheck's integration into Contakt World's offerings, business plan and growth strategy; Healthchecks's prospects as a platform and service; Contakt World's ability to scale and sell HealthCheck; Contakt World's ability to deploy a successful vaccine passport; and Contakt World's ability to leverage Healthcheck going forward. Although forward-looking statements contained in this press release are based upon what management of Contakt World believes are reasonable assumptions, there can be no assurance that forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The forward-looking statements may also be affected by risks and uncertainties in the business of Contakt World, including those described in the Company's public filings available on www.SEDAR.com. Contakt World undertakes no obligation to update forward-looking statements if circumstances or management's estimates or opinions should change except as required by applicable securities laws. The reader is cautioned not to place undue reliance on forward-looking statements. The Canadian Securities Exchange (CSE) has not reviewed, approved or disapproved the content of this news release.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/94332

News Provided by Newsfile via QuoteMedia

The Conversation (0)
Sona Nanotech Updates on Dalhousie Efficacy Study and New NCL Results

Sona Nanotech Updates on Dalhousie Efficacy Study and New NCL Results

Sona Nanotech Inc. (CSE: SONA) (OTCQB: SNANF) (the "Company" or "Sona") announces positive interim results from its study with The Giacomantonio Immuno-Oncology Research Group at Dalhousie University (the "Study"). An update received by the Company indicates that all tumors treated within the Study to date with a single Targeted Hyperthermia Therapy ("THT") treatment shrunk within the first 24 hours, with an average reduction in size of 80% compared to matched controls.

Study Principal Investigator, Dr. Carman Giacomantonio, comments, "Our initial assessment documented that in cohorts of seven animals, 7/7 of treated triple negative breast cancer mouse tumors bearing gold nanorods responded with an average reduction in tumor volume of 80% following a single treatment with near infrared light in comparison with untreated 'control' tumors. Interestingly, in all cases we observed responses (tumor shrinkage) in distant, untreated tumors supporting the hypothesis that our observations are consistent with systemic immunogenic responses. This observation will be a significant focus of our research going forward. While we are encouraged by these initial results, there is still significant work to be completed. The studies are designed to enable and identify statistical significance which will be achieved with the completion of the full Study."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
ARway.ai Announces Major 300,000 SQ FT or 30,000 M. Retail Store Pilot of its AR Navigation Platform

ARway.ai Announces Major 300,000 SQ FT or 30,000 M. Retail Store Pilot of its AR Navigation Platform

ARway.ai ("ARway" or the "Company") (CSE:ARWY)(OTCQB:ARWYF)(FSE:E65) is an AI powered Augmented Reality Experience platform with a disruptive no-code, no beacon spatial computing solution enabled by visual marker tracking with centimeter precision is pleased to announce its new partnership with Megatek Albania's leading home improvement and do-it-yourself (DIY) retailer. This groundbreaking collaboration is set to bring an unprecedented retail experience to the Albanian market, beginning with a pilot program at Megatek's expansive flagship store that spans more than 323,000 square feet

The successful implementation of ARway's technology in Megatek's flagship store will pave the way for future deployments across more locations and similar stores, signaling a significant growth and revenue opportunity for both companies.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
NEO Battery Materials Announces Change of Auditor to MNP LLP

NEO Battery Materials Announces Change of Auditor to MNP LLP

NEO Battery Materials Ltd. (" NEO " or the " C o mpan y ") ( T S X V : NBM ) ( OTC: NBMFF ), a low-cost silicon anode materials developer that enables longer-running, rapid-charging lithium-ion batteries, is pleased to announce that it has changed its auditors from DeVisser Gray LLP (" Former Auditor ") to MNP LLP (" Successor Auditor "), effective March 19, 2024.

NEO Battery's board of directors accepted the resignation of DeVisser Gray LLP and appointed MNP LLP as the new auditor of the Company, effective March 19, 2024, until the Company's next annual general meeting of shareholders.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

NANALYSIS ANNOUNCES CLOSING OF PREVIOUSLY ANNOUNCED BEST EFFORTS PROSPECTUS EXEMPT OFFERING PURSUANT TO THE LISTED ISSUER EXEMPTION AND CONCURRENT PRIVATE PLACEMENT

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES ./

Nanalysis Scientific Corp. (TSXV: NSCI) (the " Company " or " Nanalysis ") is pleased to announce that it has closed its prospectus exempt offering of units (the " Offering ") and concurrent brokered "best efforts" prospectus exempt offering of units (the " Concurrent Offering" ), as announced on March 6, 2024 . A total of 11,111,110 units (the " Units ") were issued at a price of $0.45 per Unit for gross proceeds of $4,999,999.50 . A total of 8,888,888 Units were issued pursuant to the Offering and 2,222,222 Units were issued pursuant to the Concurrent Offering.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
ARway.ai Announces EWROS as New Partner in Turkey for its Augmented Reality Navigation Experience Platform

ARway.ai Announces EWROS as New Partner in Turkey for its Augmented Reality Navigation Experience Platform

ARway.ai ("ARway" or the "Company") (CSE:ARWY)(OTCQB:ARWYF)(FSE:E65) is an AI powered Augmented Reality Experience platform with a disruptive no-code, no beacon spatial computing solution enabled by visual marker tracking with centimeter precision is pleased to announce a paid partner deal with EWROS, a leading developer of automation systems software based out of Turkey. This new partner is another step in ARway.ai's expansion, aligning with EWROS's recognized position in the region as a premier automation solutions provider

EWROS becomes an integral part of the ARway ecosystem, licensing ARway's innovative platform for large-scale projects within the region. This partnership allows EWROS to leverage ARway's cutting-edge AR technology in conjunction with their existing IoT deployments, thereby offering a comprehensive tech stack to their clientele.

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less
Sona Nanotech Announces Filing of Provisional Patent Application

Sona Nanotech Announces Filing of Provisional Patent Application

Sona Nanotech Inc. (CSE: SONA), (OTCQB: SNANF) (the "Company" or "Sona") announces that it has submitted a provisional patent application with the United States Patent and Trademark Office (USPTO), for its proprietary photothermal light device, entitled, "ENDOSCOPE WITH EMR OPTICAL FIBER AND THERMAL SENSOR FOR PHOTOTHERMAL THERAPY".

A prototype of Sona's medical laser was engineered in conjunction with Minnetronix Medical to apply non-thermal, 860 nanometer wavelength high intensity infrared laser light. The device has been designed for use with Sona's patented/patent pending biocompatible gold nanorods which efficiently convert the non-thermal light energy into heat. The device has controls to regulate the intensity and duration of the light exposure and to permit a user to monitor and control the temperature generated in tissue. The device is currently being used for the Company's ongoing pre-clinical efficacy study of its Targeted Hyperthermia Therapy cancer treatment at Dalhousie University.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×